228 related articles for article (PubMed ID: 35860585)
1. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
2. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
3. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
[TBL] [Abstract][Full Text] [Related]
5. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
6. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
7. Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study.
Nie C; Lv H; Liu Y; Chen B; Xu W; Wang J; Chen X
Front Oncol; 2021; 11():741865. PubMed ID: 34631579
[TBL] [Abstract][Full Text] [Related]
8. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
9. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
Liu Y; Ge Q; Xu S; Li K; Liu Y
Front Oncol; 2022; 12():942678. PubMed ID: 36059654
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
14. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma.
Li Q; Su T; Zhang X; Pan Y; Ma S; Zhang L; Zhang X; Gao X
Cancer Manag Res; 2022; 14():3037-3046. PubMed ID: 36275784
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.
Wu Y; Li P; Zhu Y; Zhang F; Su L; Ye Y; Huang Y; Zhang M
Am J Transl Res; 2023; 15(3):1973-1981. PubMed ID: 37056822
[TBL] [Abstract][Full Text] [Related]
16. Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study.
Nie C; Xu W; Lv H; Gao X; Li G; Chen B; Wang J; Liu Y; Zhao J; He Y; Wang S; Chen X
Front Pharmacol; 2022; 13():1043217. PubMed ID: 36467052
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
Zhang S; Wang X; Gu H; Liu JQ
Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
Liu S; Zhi W; Zhang L
J Cell Mol Med; 2023 Oct; 28(5):e18008. PubMed ID: 37891706
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]